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Abstract  51 
 52 
Cornelia de Lange Syndrome is a multisystem developmental disorder typically caused by mutations in 53 
the gene encoding the cohesin loader NIPBL. The associated phenotype is generally assumed to be 54 
the consequence of aberrant transcriptional regulation. Recently, we identified a missense mutation in 55 
BRD4 associated with a Cornelia de Lange-like syndrome, that reduces BRD4 binding to acetylated 56 
histones. Here we show that, although this mutation reduces BRD4-occupancy at enhancers it does 57 
not affect transcription of the pluripotency network in mouse embryonic stem cells. Rather, it delays the 58 
cell cycle, increases DNA damage signalling, and perturbs regulation of DNA repair in mutant cells. 59 
This uncovers a role for BRD4 in DNA repair pathway choice. Furthermore, we find evidence of a similar 60 
increase in DNA damage signalling in cells derived from NIPBL-deficient individuals, suggesting that 61 
defective DNA damage signalling and repair is also a feature of typical Cornelia de Lange Syndrome.  62 
 63 
Introduction 64 
Cornelia de Lange Syndrome (CdLS) is a clinically distinctive neurodevelopmental disorder 65 
(OMIM:122470). Disease severity varies greatly and patients can suffer from a range of symptoms 66 
including: a characteristic facial appearance, upper limb abnormalities, intellectual disability and 67 
delayed growth1. CdLS is described as a ‘cohesinopathy’1 - most cases can be attributed to 68 
heterozygous loss of function mutation in NIPBL encoding a protein involved in loading of the cohesin 69 
complex onto chromatin2. Mutation in genes encoding cohesin complex proteins SMC1, SMC3 and 70 
RAD21, or HDAC8 (SMC3 deacetylase), have also been identified in CdLS-like probands2. However 71 
cells from CdLS patients have no obvious defects in sister chromatid cohesion3, and individuals with 72 
mutations in SMC1, SMC3 and RAD21 are often considered ‘atypical’ in terms of facial appearance and 73 
growth, and are less likely to have limb defects than those with NIPBL mutations4. 74 
Dysregulated gene expression has been proposed to be the main mechanism underlying CDLS5,6. 75 
Mutations in genes encoding chromatin regulators unrelated to cohesin, such as ANKRD11, KMT2A, 76 
AFF4 and the bromodomain and extra-terminal domain (BET) protein BRD4, have been reported to 77 
cause CdLS-like phenotypes1 suggesting that chromatin dysregulation may play a role in CdLS as well. 78 
Additionally, increased sensitivity to DNA damage has been reported in CdLS patient cells7, but the 79 
mechanism underlying this defect is unknown and its participation in the disease aetiology remains 80 
unclear.  81 
Recently, we described de novo deletion and missense mutations in BRD4 associated with a clinical 82 
phenotype overlapping CdLS8.  BRD4 binds acetylated lysines residues in histones H3 and H4 through 83 
its two N-terminal bromodomain domains (BD). BRD4 localises to promoters and enhancers of active 84 
genes and is particularly enriched at super enhancers (SEs)9,10. BRD4 is a key regulator of transcription;  85 
through its C-terminal domain it recruits positive transcription elongation factor (P-TEFb) and the 86 
Mediator complex to promoters and enhancers, whilst its extra-terminal domain confers transcriptional 87 
activation through the recruitment of CHD4, JMJD6, and NSD311,12. 88 
 3 
The CdLS-associated BRD4 missense mutation is in the second bromodomain (BD2) 89 
(NM_058243.2:c.1289A>G, p.(Tyr430Cys), termed here as Y430C (Figure 1a), and results in 90 
decreased binding to acetylated histones8. To gain further insights into the mechanisms underlying 91 
CdLS, and the role of BRD4, we investigated the phenotype of mouse embryonic stem cells (mESCs) 92 
homozygous for the orthologous amino acid substitution in mouse Brd4 (actually p.Tyr431Cys but for 93 
simplicity here termed Brd4Y430C). Here we show that the decreased affinity for acetylated lysines results 94 
in diminished occupancy of BRD4Y430C at cis regulatory elements (CREs) across the genome, including 95 
the super-enhancers of pluripotency genes.  However, we find no evidence of altered transcription of 96 
the pluripotency network in these cells. Instead, we report increased and more persistent DNA damage 97 
signaling and cell cycle checkpoint activation in Brd4Y430C mESCs. We show increased persistent foci 98 
of the DNA damage response (DDR) protein 53BP1 upon double-strand break (DSB) induction in Brd4 99 
mutant cells. 53BP1 is a key factor in the regulation of DNA repair pathway choice that inhibits repair 100 
by homologous recombination (HR). We also show increased foci of the downstream effectors of 101 
53BP1, Rif1 and the Mad2l2 (Rev7) subunit of the shieldin complex in the mutant cells13–22 and 102 
decreased recruitment of RAD51, suggesting impaired HR repair. Further, we show that cells from 103 
CdLS patients harbouring mutations in NIPBL have a similar DDR phenotype, indicating there may be 104 
a previously underappreciated role for the DNA damage response in the aetiology of CdLS. 105 
 106 
Results  107 
 108 
Reduced occupancy of Y430C-BRD4 at cis-regulatory elements 109 
Our previous work suggested that the Y430C mutation abrogates BRD4 binding to acetylated histones 110 
in vitro and in vivo8. To determine the genome-wide effect of this reduced affinity we carried out BRD4 111 
ChIP-seq in two independently-generated mESCs lines engineered by CRISPR-Cas9 to carry the 112 
Y430C mutation on both alleles of Brd4. Immunoblotting showed that the Y430C mutant BRD4 protein 113 
was present at levels equivalent to that of BRD4 in wild-type cells (Supplementary figure 1a) and was 114 
efficiently immunopreciptated by anti-Brd4 antibodies (Supplementary figure 1b). As expected, BRD4 115 
was enriched over CREs (SEs, typical enhancers and promoters) in both wild-type (WT) and Y430C 116 
cells (Figure 1b, Supplementary figure 1c).  However, consistent with a lowered affinity for acetyl-117 
lysines, there was a general decrease in BRD4 occupancy in both clones of Y430C cells, most striking 118 
at enhancers and super-enhancers (SE) (Figure 1c,d, Supplementary figure S1c-d). In mESCs, BRD4 119 
binding to SEs regulates the transcription of stem cell identity genes9. As BRD4Y430C occupancy is 120 
decreased at the SEs of a number of stem cell identity genes, this suggests that there might be 121 
decreased transcription of these genes in mutant cells.  122 
 123 
Decreased occupancy of mutant BRD4 at CREs does not have major effects on 124 
transcription in mESCs 125 
The use of inhibitors that competitively bind the acetyl-lysine binding pockets of BET proteins has shown 126 
that loss of BRD4 binding disrupts the expression of target genes, especially genes regulated by SEs 127 
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10. Consistent with this, we observed decreased expression of the SE associated genes Nanog, Myc, 128 
Klf4 and Oct4 in WT mESCs after treatment with JQ1 (Figure 2a). However, we did not observe any 129 
decrease in levels of Klf4, Nanog and Oct4 mRNAs in Y430C mESCs by RT-qPCR (Figure 2b).  130 
To determine whether mRNA stability was masking an effect on transcription per se, we performed 4-131 
thiouridine sequencing (4SU-seq) to assay nascent transcription. Transcription was surprisingly similar 132 
between WT and Y430C mESCs (Pearson correlation coefficient=0.98) (Figure 2c,d and data from an 133 
independent Y430C in Supplementary figure 2a). In particular, decreased BRD4 binding at SEs did not 134 
lead to transcriptional changes at stem cell identity genes (Figure 2c-e, replicate in Supplementary 135 
figure 2b), or of eRNAs at the SEs themselves (Figure 2f, Supplementary figure 2c). Due to 136 
normalization, these experiments could not rule out that transcription is not globally decreased in the 137 
mutant ESCs. We therefore performed a spike-in RNA-seq experiment, using RNA from Drosophila 138 
cells for normalization. Again, we did not observe any major transcriptional differences between WT 139 
and Y430C cells (Supplementary figure 2d&e). We conclude that the decreased occupancy of 140 
BRD4Y430C at CREs in mESCs is not sufficient to affect the transcription of associated genes.  141 
This result is surprising, given BRD4’s well documented roles in transcriptional regulation. Therefore, 142 
we also analysed gene expression in embryonic fibroblasts (MEFs) that had been derived from either 143 
wild-type or Brd4Y430C homozygous embryos8. In contrast to homozygous null Brd4 embryos, which 144 
show significant growth retardation at E13.5 of embryonic development, Brd4Y430C homozygous 145 
embryos are reported to be morphologically indistinguishable from wild-type at this stage8 suggesting 146 
the absence of major developmental gene regulation. However, analysis of  gene expression shows 147 
significant alteration of gene expression between wild-type and mutant MEFS  (Supplementary figure 148 
3). We consider this difference in the transcriptional consequences of Brd4Y430C between ESCs and 149 
MEFS may reflect the differing dependencies on epigenetic regulators at different stages of 150 
development. 151 
 152 
Y430C-BRD4 mESCs have a delayed cell cycle and increased cell cycle checkpoint 153 
activation 154 
We noted that BRD4Y430C mESCs grew slower and showed an accumulation of cells in G2/M (33.7%), 155 
compared to their WT counterparts (27.8%) (Figure 3a, b, Supplementary Figure 4a).  This observation, 156 
together with the recently reported roles for BRD4 in the DDR and DNA repair23–26 led us to investigate 157 
potential DDR defects in mutant cells. 158 
The DDR allows coordination between DNA repair and cell cycle progression. Recognition of DNA 159 
damage by sensor proteins initiates a cascade that results in the phosphorylation and activation of the 160 
checkpoint kinases CHK1 and CHK2, delaying or blocking cell cycle progression27. CHK1 is the main 161 
kinase required for delay at G2/M27. To determine whether the altered cell cycle in BRD4Y430C cells is 162 
associated with increased activation of the G2/M checkpoint, we analysed CHK1 phosphorylation 163 
(CHK1-P) after treatment with neocarzinostatin (NCS), a radiomimetic drug which induces mainly DSBs. 164 
CHK1-P is increased in both WT and BRD4Y430C mESCs cell lines 1hr post NCS treatment, which is 165 
resolved by 16hrs. However, the levels of CHK1-P are higher in BRD4Y430C mESCs (Figure 3c, 166 
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Supplementary Figure 4b and Supplementary Figure 9), suggesting an increased checkpoint activation.  167 
These results suggest a defect in DNA repair or signaling caused by BRD4Y430C. BRD4 has been shown 168 
to be directly involved in DNA repair through the transcriptional regulation of DNA repair proteins24,25,28. 169 
However, 4SU-seq showed that transcription of genes encoding DNA repair proteins was unaffected in 170 
BRD4Y430C mESCs (Supplementary figure 4c, d) and immunoblotting showed that overall levels of 171 
53BP1 and Rad51 were not significantly altered in the mutant cells (Supplementary figure 4e). 172 
 173 
Y430C-BRD4 mESCs have increased DDR signalling 174 
Although not being directly recruited to DSBs29 (Supplementary figure 5a), BRD4 restricts the DDR and 175 
depletion of BRD4 isoform B leads to increased DDR signalling23. We therefore tested whether 176 
BRD4Y430C affects DNA damage signalling. mESCs have constitutively high levels of gH2AX, even in 177 
the absence of a DNA damaging stimulus30. We therefore used 53BP1 as a marker of DDR. 53BP1 is 178 
recruited to DSBs, spreads to form microscopically visible foci, and acts as a scaffold for the recruitment 179 
of further DSB response proteins, to regulate the choice of DNA repair pathway and to promote cell 180 
cycle checkpoint signalling31.  181 
Immunofluorescence showed formation of multiple 53BP1 foci, representing DNA damage sites, upon 182 
DSB induction (1h after NCS treatment). These foci are only present at low levels prior to NCS treatment 183 
and decrease in number at 16 and 20h post treatment, as cells repair the damage (Figure 4a). 184 
Supporting the hypothesis that the Y430C mutation impairs the role of BRD4 in DDR restriction, we 185 
observed that 53BP1 foci are larger in BRD4Y430C mESCs than in WT (Figure 4a&b). In addition, whilst 186 
the number of 53BP1 foci in WT cells returns to pre-treatment levels at 16 and 20h time points, the 187 
number of 53BP1 foci in BRD4Y430C cells remains higher (Figure 4a&c, Supplementary figure 5b&c), 188 
suggesting that DNA repair itself could be impaired.  189 
During our analysis of transcription, we found potential evidence for aneuploidy for chromosome 11 in 190 
BRD4Y430C cells. Concerned that the DNA repair defects we observed in BRD4Y430C cells were caused 191 
by aneuploidy rather than the BRD4 mutation, we repeated the 53BP1 staining using WT and BRD4Y430C 192 
mESCs that had been confirmed to have a diploid karyotype. This analysis confirmed that the increased 193 
number and size of 53BP1 foci after NCS treatment is specific to cells carrying the BRD4Y430C mutation, 194 
and not an additional chromosome 11 (Supplementary figure 6). 195 
Given the accumulation of BRD4Y430C cells in S/G2 (Figure 3), one possible origin of 53BP1 foci is the 196 
formation of Oct1/PTF/transcription (OPT) domains arising as a consequence of problems encountered 197 
in S-phase and propagated through mitosis into the subsequent G132,33. Indeed inhibition of BRD4 by 198 
BET inhibitors has been reported to induce replication stress34. However, immunofluorescence showed 199 
that 53BP1 foci present in BRD4Y430C cells, either with or without NCS treatment, do not co-localise with 200 
OPT domains marked by Oct1 (Supplementary Figure 7). 201 
 202 
Defective DSB repair in Y430C-BRD4 cells  203 
For the most part, DSBs are repaired by either non-homologous end-joining (NHEJ) or HR35. Use of the 204 
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appropriate pathway is important for faithful repair and is determined by antagonistic recruitment of 205 
53BP1 and BRCA131. 53BP1 inhibits DSB end resection, the initial step of HR, thereby promoting NHEJ 206 
and inhibiting HR. Downstream effectors of 53BP1 in the regulation of resection include RIF119–22 and 207 
the recently identified shieldin complex  (SHLD1, SHLD2, SHLD3 and MAD2L2)13–18. If timely repair 208 
does not occur by NHEJ, BRCA1 promotes the release of RIF1, leading to end-resection and HR.  209 
As BRD4Y430C mESCs show increased numbers and size of 53BP1 foci compared to WT cells, we 210 
reasoned that there may also be increased recruitment of the downstream effectors of 53BP1 such as 211 
RIF1 and MAD2L2. Indeed, we observed an increased number of RIF1 (Figure 5a&b, Supplementary 212 
figure 5d&e) and MAD2L2 (Figure 5c&d, Supplementary figure 5f&h) foci in BRD4Y430C compared to 213 
WT cells at all time-points, similar to 53BP1. Conversely, we observed a significant decrease in the 214 
number of foci of RAD51, a protein necessary for HR repair, in mutant cells at 1 hour post NCS (Figure 215 
6a&b, Supplementary figure 5h&i), suggesting a repression of HR. Given our cell cycle analysis (Fig 216 
3b) this cannot be simply explained by fewer cells in S/G2. Given the role of the shieldin complex in 217 
protecting DSB end-resection, we propose that the Y430C BRD4 mutation leads to an altered balance 218 
between NHEJ and HR, consistent with the synthetic lethality observed between BRD4 and PARP 219 
inhibitors25,28. 220 
 221 
Increased number and size of 53BP1 foci in NIPBL mutant lymphoblastoid cell lines   222 
To see if the DDR defect that we have observed in the presence of the BRD4Y430C  would also be 223 
apparent in cells carrying other CdLS mutations, we utilised two lymphoblastoid cell lines (LCL) 224 
previously derived from CdLS patients with heterozygous mutations in NIPBL, Ile1206del36 and 225 
Arg2298His37. These LCLs have significantly more, and larger, 53BP1 foci per cell compared to a WT 226 
LCL, in the absence of any exogenous damage (Figure 6c-e, Supplementary figure 8a&b), This 227 
suggests that increased DDR signalling and/or impaired DNA repair pathway choice balance may be a 228 




We previously showed that a Y430C-BRD4 mutation, and BRD4 haploinsufficiency, cause a CdLS-like 233 
syndrome8. The severe developmental phenotypes associated with CdLS are generally thought to be 234 
due to aberrant gene regulation. Here however, we show that BRD4Y430C, whilst lowering the affinity of 235 
BRD4 to acetylated lysine residues and decreasing its occupancy at enhancers and SEs, causes minor 236 
changes in transcription in mESCs, in contrast to the major transcriptional changes caused by the 237 
profound loss of BRD4 binding induced by BET inhibitors.  Instead, we provide evidence that the 238 
BRD4Y430C hypomorph causes increased G2/M checkpoint activation, aberrant DDR signalling, and an 239 
altered focal accumulation of proteins that promote NHEJ and inhibit HR – 53BP1 and the shieldin 240 
complex. Conversely there is a depletion of foci containing HR proteins (Rad51), suggesting a defect 241 
in HR. Our results suggest a role for BRD4 in the regulation of DNA repair pathway choice and are 242 
consistent with recent results from an siRNA screen in human cell lines that suggest that BRD4 243 
deficiency leads to less repair by HR and more by NHEJ 38. Whether BRD4 mutation affects repair by 244 
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HR at specific regions in the genome, or globally, remains to be investigated.  For example, different 245 
levels of histone acetylation in different chromatin environments – e.g. heterochromatin vs euchromatin 246 
- upon DNA damage may recruit different amounts of BRD439,40. Alternatively, as well as interacting 247 
with NIPBL, Brd4 has been reported to interact with a number of proteins involved in DNA damage 248 
sensing and repair, including Rif1 of the Sheildin complex.8,41 We cannot exclude that impaired BRD4 249 
function in BRD4Y430C cells affects the formation of DSBs themselves, for example by preventing the 250 
accumulation of R-loops 23,38,42. 251 
We observed a similar focal accumulation of 53BP1 in cells from CdLS patients with mutations in NIPBL. 252 
Could aberrant DDR and DNA repair choice, or perhaps elevated DNA damage per se, therefore 253 
account for some of the phenotypes associated with CdLS? Congenital mutation in many different 254 
genes involved in cell cycle progression and DNA repair, are - like CdLS – generally associated with 255 
intrauterine growth retardation and short stature43. Similarly, microcephaly also results from mutation in 256 
genes associated with S phase progression (ATR, ATRIP, CtIP - Seckel syndrome; DNA ligase IV – 257 
lig4 syndrome; XRCC4 – microcephalic primordial dwarfism44–46). Clinically, there is strongest 258 
phenotypic overlap between CdLS and Rubinstein-Taybi syndromes (RTS) - including arched eyebrows 259 
and other shared distinctive facial features. RTS is cause by mutations in p300 or CREBBP. These 260 
lysine acetyltransferases have recently been shown to be important for acetylating proteins involved in 261 
the DDR and DNA repair 47. NIPBL and cohesin are also both involved in DNA damage signalling and 262 
repair 48 and CdLS patient cells carrying NIPBL mutations display an increased DNA damage 263 
sensitivity49. Even though we cannot discount that BRD4 mutation in CdLS cases – Y430C, or 264 
heterozygous deletions, cause aberrant transcriptional regulation in cell types other than ESCs, our 265 
results suggest that dysregulation of DDR and repair may contribute to the aetiology of CdLS.  266 
 267 
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KEY RESOURCES TABLE 435 
Antibodies SOURCE IDENTIFIER 
BRD4 Bethyl  Cat# A301-985A-M 
53BP1 Novus Cat# NB100-304 
Normal Rabbit IgG Santa Cruz Cat# sc-2025 
CHK1 Abcam  Cat# ab47574 




Lamin B Santa Cruz Cat# sc-374015 
MAD2L2 Abcam  Cat# ab180579 
RIF1 A kind gift from Sara 
Buonomo 
Rabbit anti–mouse 
Rif1 serum 1240 50 
RAD51 for IF 





gH2AX Merck-Millipore Cat# 05-636 
gTubulin Abcam Ab11316 
Goat anti-Rabbit IgG, secondary, Alexa Fluor 488 Invitrogen Cat# A11034 
Donkey anti-Rabbit IgG, secondary, Alexa Fluor 586 Invitrogen Cat# A10042 
 436 






































BRD4-WT ChIP-seq  This paper GSE130659 
BRD4-Y430C ChIP-seq This paper GSE130659 
WT 4sU-seq This paper GSE130659 
Y430C 4sU-seq This paper GSE130659 
WT Spike-in RNAseq This paper  GSE130659 
Y430C Spike-in RNAseq This paper  GSE130659 




Software and Algorithms 







FACSDiva software BD Bisoscience  
TopHat  Trapnell et al., 2012 https://ccb.jhu.edu/so
ftware/tophat/index.s
html 
Cufflinks Trapnell et al., 2012 http://cole-trapnell-
lab.github.io/cufflinks/ 
Deeptools2 Ramirez et al., 2016 http://deeptools.readt
hedocs.io/en/latest/in
dex.html 
SAMtools  Li et al., 2009 http://samtools.sourc
eforge.net/ 
 441 
Cell culture  442 
Y430C-BRD4 mutant and corresponding wild-type mouse embryonic stem cells (mESCs) were 443 
generated by CRISPR Cas9 genome editing in 46C mESCs as described previously 8. NIPBL I1206del 444 
and R2298H lymphoblastoid cell lines (LCLs) were obtained from patients36,37. mESCs were cultured in 445 
GMEM medium (GIBCO; 11710035) supplemented with 10% Fetal Calf Serum (FCS), 5% 446 
penicillin-streptomycin, 1 mM sodium pyruvate (GIBCO; 11360070), 1X non-essential amino 447 
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acids (GIBCO; 11140050), 50 µM 2-Mercaptoethanol (GIBCO; 31350010), 2 mM L-glutamine 448 
and 500U/ml Leukaemia Inhibitory Factor (in house). Lymphoblastoid cell lines (LCLs) were 449 
grown in RPMI 1640 medium (GIBCO; 11875093) supplemented with 15% FCS and 2 mM L-450 
glutamine. All cells were grown at 37°C in a 5% CO2 humidified atmosphere.  451 
ChIP-qPCR 452 
Cells were harvested by trypsinising and fixed with 1% formaldehyde (Thermo Fisher; 28906) in media 453 
(25°C, 10 min). This reaction was quenched with 0.125 M glycine for 5 min. ChIP-qPCR was performed 454 
as described previously8 (see table for antibodies).  DNA was purified using the QIAquick PCR 455 
Purification kit (Qiagen, 28104). Input samples were diluted to 1%, and all samples diluted a further 456 
10-fold, in ddH20. SYBR-green based qPCR reactions were performed in a final volume of 20 µl 457 
containing diluted ChIP DNA, SYBR select master mix (ThermoFisher Scientific; 4472908) and 0.25 458 
µM/L of each primer (see table). Concentration of IPs are relative to 1% input.  459 
 460 
ChIP-seq  461 
ChIP was carried out as above. After purification, DNA was eluted in 20 μl and libraries were 462 
prepared for ChIP and input samples as previously described51. Samples were sequenced at BGI 463 
(Hong Kong; 50-bp single-end reads) using the HiSeq 4000 system (Illumina). Fastq files were quality 464 
controlled using FastQC and mapped to the mm9 genome using Bowtie2 (parameters: default). Sam 465 
files were converted to bam files and sorted using SamTools. Homer was used to make tagdirectories 466 
(makeTagDirectory, parameters: –unique, fragLength 150) and bedgraphs (makeUCSCfile, 467 
parameters: default). For visualisation of BRD4 data, bedgraphs were uploaded to the genome browser 468 
UCSC. Peak calling was carried out using MACS2; Duplicates were filtered (filterdup, parameters:--469 
keep-dup=1), peaks called (callpeaks, parameters: -B --nomodel -p 1e-5) and differential peaks were 470 
found (bdgdiff, parameters: -g 60 -l 250).  471 
deepTools2 was used to make heatmaps; score files were made across specific genomic regions 472 
(computeMatrix, parameters:  scale-regions scale regions –b 500 –a 500 –bs 50 –bl mm9 blacklist) and 473 
these were used to plot heatmaps (plotHeatmap, parameters: --colormap RdBluYl reverse).  474 
JQ1 treatment  475 
1 mM BRD4 inhibitor JQ1+, or its inactive form JQ1- (Merck; 500586) (diluted in DMSO), were added 476 
to mESC media at a final concentration of 300 nM. JQ1+/-. WT and Y430C mESCs were incubated at 477 
37°C with JQ1+/- supplemented media for 48 hrs. Total RNA was extracted from cells using the RNeasy 478 
Plus Mini Kit (Qiagen; 74134) and 1 µg RNA was used for cDNA synthesis with SuperScript II Reverse 479 
Transcriptase (ThermoFisher Scientific; 18064-014) as per manufacturer’s instructions. cDNA was 480 
diluted 1:500 for qPCR analysis. qPCR reactions were performed as above (see table for primers). 481 
Concentration of JQ1+ cDNA was calculated relative to JQ1- (arbitrarily set to 1).    482 
RT-PCR 483 
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RNA was extracted from cells using the RNeasy Mini Kit (Qiagen; 74104) using spin technology, with 484 
an additional on-column DNA digestion using the RNase-Free DNase Set (Qiagen; 79254). cDNA was 485 
synthesised from 1 μg RNA using SuperScript II Reverse Transcriptase (ThermoFisher Scientific; 486 
18064-014) as per manufacturer’s instructions. cDNA was diluted 1 in 25 for qPCR analysis. SYBR-487 
green based qPCR reactions were performed in a final volume of 20 μl containing diluted cDNA, SYBR 488 
select master mix (ThermoFisher Scientific; 4472908) and 0.5 μM/l of region specific intron-spanning 489 
primer pairs. 490 
4sU-seq 491 
4sU RNA was generated and isolated as described previously 52,  with the following changes:  cells 492 
were incubated at 37°C with 4sU-supplemented medium for 20 min. The reaction was incubated with 493 
Biotin-HPDP with rotation for 1.5 hours at RT. For recovery of biotinylated 4sU-RNA, 1 µl of streptavidin 494 
beads was added per μg of RNA. Columns were washed using 900 µl washing buffer and RNA was 495 
eluted by 2 sequential additions of 100 µl Elution Buffer (100 mM DTT) to the column and eluates 496 
combined. RNA was further purified using the RNAeasy MinElute Clean-up kit (Qiagen; 74204) 497 
according to the manufacturer’s guidelines, eluting in 20 µl water. 1 μl of 4sU-labeled RNA was quality-498 
checked by running on a 2100 Bioanalyzer Instrument (Agilent). 499 
To make 4sU sequencing libraries, 4sU labelled RNA was first depleted of rRNA using the Low Input 500 
Ribominus Eukaryotic System V2 (ThermoFisher Scientific; A15027) as per the manufacturer’s 501 
instructions. 600 ng of 4sU labelled RNA was used as input, and eluted in 5 µl RNase free water. All of 502 
the resulting rRNA free RNA was used to prepare 4sU sequencing libraries, using NEBnext Ultra 503 
Directional RNA library prep kit of Illumina (NEB; E7420). RNA fragmentation was carried out at 94°C 504 
for 15 min, as suggested for intact RNA. Libraries were indexed with Multiplex Oligos for 505 
Illumina® (Index Primers Set 1) (NEBnext; E7335) and amplified by PCR for 13 cycles. Library 506 
concentration and correct size distribution was confirmed on the Agilent 2100 Bioanalyser with the DNA 507 
HS Kit. Libraries were sequenced at BGI (Hong Kong; 100-base paired-end reads) using the HiSeq 508 
4000 system (Illumina).  509 
Fastq files were quality controlled using FastQC and mapped to the mm9 genome using tophat 510 
(parameters: --library-type fr-firststrand -r 200). Homer was used to make tagdirectories 511 
(makeTagDirectory, parameters: -unique -sspe -flip -fragLength 150), and to make bedgraphs for 512 
visualisation on UCSC (makeUCSCfile, parameters: -strand separate -style rnaseq). Cufflinks was used 513 
for peak calling; transcripts were assembled for individual experiments (cufflinks, parameters: –m 200 514 
–library-type fr) and both replicates of WT and Y430C were combined to form one assembly (cuffmerge, 515 
parameters: default).  Differentially expressed peaks were determined from this assembly using cuffdiff 516 
(Cuffdiff. Parameters: default).  517 




Spike-in RNA-seq 521 
S2 cells were cultured in Schneider’s Drosophila Medium (Invitrogen; 11720-034), supplemented with 522 
10% heat-inactivated FCS and 5% penicillin-streptomycin. Cells were passaged once they reached a 523 
density of ~2x107 cells/ml and seeded at a density of ~4x106. Cells were grown at 28°C in a 5% CO2 524 
humidified atmosphere. Cells were frozen at a density of ~1x107 cells/ml in 45% conditioned 525 
Schneider’s Drosophila Medium media (containing 10% FCS), 45% fresh Schneider’s Drosophila 526 
Medium supplemented with 10% FCS, and 10% DMSO, and stored in liquid nitrogen.  527 
mESCs and S2 cells were harvested and counted. 0.2 million S2 cells were mixed with 10 million 528 
mESCs, and RNA was extracted using the RNeasy Mini Kit (Qiagen; 74104) using spin technology, 529 
with an additional on-column DNA digestion using the RNase-Free DNase Set (Qiagen; 79254). RNA 530 
was depleted of rRNA and RNA-seq libraries prepared as for the 4sU-seq.  531 
Growth assay  532 
WT and Y430C mESCs were each seeded in 4 wells of a 6 well plate (1 x 104 cells/well). WT and Y430C 533 
cells from 1 well were trypsinised and counted at 24, 48, 72 and 96 hrs post seeding. Counting was 534 
carried out manually using a haemocytometer. The addition of trypan blue dye allowed for the exclusion 535 
of dead cells.  536 
Flow cytometry  537 
2 million mESCs were fixed in 70% ethanol (in PBS) at 4oC for 1 hr. Fixed cells were centrifuged at 538 
300g at 4oC for 5 min, washed twice with PBS and resuspended in 500 µl PBS. 20 µg RNase A was 539 
added and cells were incubated at 37oC for 10 min. Cells were stained with propium iodide at a final 540 
concentration of 50 µg/ml. Acquisition was carried out on a BD LSRFortessa cell analyser, collecting 541 
25,000 events per sample. Results were analysed using BD FACSDiva 8.0.1 and gated cells were 542 
manually categorized into cell cycle stages G0/G1, S and G2/M. 543 
NCS treatment and CHK-1 protein western blots 544 
Cells were incubated with mESC media supplemented with neocarzinostatin (Sigma; N9162) (NCS), to 545 
a final concentration of 25 ng/ml, for 15 min at 37°C. Cells were then washed with PBS and fresh, non-546 
supplemented media was added. Protein was either extracted straight away, or after incubation at 37°C 547 
for varying lengths of time. Ice-cold RIPA buffer (150 mM sodium chloride; 1.0% NP-40; 0.5% sodium 548 
deoxycholate; 0.1% SDS; 50 mM Tris, pH 8.0) was added to plates (1 ml per 107 cells) and cells were 549 
scraped and transferred into pre-chilled microcentrifuge tubes. Tubes were shaken at 4°C for 30 min 550 
before centrifugation at 20,000 x g for 15 min. Supernatant was retained and quantified. For western 551 
blot analysis, equal amounts of protein were boiled in 1X NuPage LDS buffer (ThermoFisher Scientific, 552 
NP0008) with 1X NuPage reducing agent (ThermoFisher Scientific; NP0004) for 5 min and separated 553 
on a 3-8% tris-acetate gel (ThermoFisher Scientific; EA0375BOX). Following electrophoresis, proteins 554 
were transferred to nitrocellulose membranes (ThermoFisher Scientific) and immunoblotted with 555 
primary antibodies overnight at 4°C.   Membranes were washed 3 X TBST and probed with HRP-556 
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conjugated secondary antibody for 1 hr at RT. After 3 more washes in TBST, membranes were 557 
incubated with SuperSignal™ West Femto Maximum Sensitivity Substrate (ThermoFisher 558 
Scientific; 34095) for 5 min and imaged using ImageQuant™ LAS 4000 (GE Healthcare). 559 
Immunofluorescence 560 
mESCs for immunofluorescence experiments were cultured on gelatinised coverslips and LCLs were 561 
grown in suspension. LCLs were harvested and resuspended in PBS to 1.8 x 105 cells/ml. 500 µl of cell 562 
suspension was added to a Shandon™ Single Cytofunnel™ (ThermoFisher Scientific; 563 
5991040), with a microscope slide attached. Slides were centrifuged at 800 rpm for 5 min, after which 564 
the LCLs had attached to the slide. All cells were fixed in 4% paraformaldehyde for 10 min and washed 565 
3X 3 min in PBS. Cells were then permeabilised in 0.5% Triton in PBS for 10 min and washed 3X 3 min 566 
in PBS. Cells were blocked in 1% BSA in PBS for 30 min at RT, incubated with primary antibody diluted 567 
in 1% BSA for 1 hr at RT and washed 3X 3 min in PBS. Cells were next incubated with secondary 568 
antibody (see table) diluted in 1% BSA for 45 min at RT, washed 3X 3 min in PBS, incubated with DAPI 569 
in PBS (250 ng/ml) for 2 min, and washed 3x 3 min in PBS. Coverslips were mounted on slides in 570 
Vectashield (Vector; H1000) mounting medium for fluorescence.  571 
All slides were viewed, and foci counted, using epifluorescence microscopes. Images were taken using 572 
confocal microscopy.  573 
Laser microirradiation of U2OS cells 574 
U2OS cells (ATCC® HTB-96™) were grown on glass coverslips and incubated with 10µM BrdU (Sigma 575 
Aldrich, #B9285) for 24h prior to microirradiation. Microirradiation was induced with a 405 nm laser 576 
diode (3 mW) focused through a 63x/1.4 oil objective on a Zeiss LSM710 confocal microscope using 577 
the following laser settings: 40% power, 50 iterations, scan speed 12.6  µsec/pixel. Cells were fixed 578 
either 10min or 2h after laser irradiation using 2% PFA and immunofluorescence was performed as 579 
described in the immunofluorescence section using gH2AX antibody (Merck-Millipore, #05-636) as 580 
positive control of DNA damage induction. Image acquisition was performed on a Leica DMI6000 581 
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Figure 1. Decreased binding of BRD4 at CREs in Y430C mESCs. a) Cartoon of BRD4 showing location of the Y430C 
mutation in the second bromodomain (BD2). b) Heatmaps show enrichment of wild-type (WT) and Y430C BRD4 ChIP over super 
enhancers (SE), typical enhancers, promoters and gene bodies. c) UCSC genome browser screenshot showing reads per 10 million
over the Klf4, extended Nanog and Sox2 loci for BRD4 ChIP-seq in WT and BRD4Y430C mESCs. Extent of SEs are shown in blue. 
Below are shown previously published ChIP-seq data for H3K27ac (ENCSR000CDE), H3K9ac (ENCSR000CGS), H3K122ac
(GSE66023) and DNase I hypersensitivity (DHS). Genome co-ordinates (Mb) are from the mm9 assembly of the mouse genome. 
Biological replicate from an independent Y430C clone are in Supplementary figure 1. d) ChIP-qPCR measuring concentration of
BRD4 ChIP DNA relative to input across the SEs of Oct4, Klf4, Nanog, and Sox2; in WT and BRD4Y430C mESCs. Data are represented
as mean +/- SEM from 3 technical replicates. 
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Figure 2. Similar transcription in WT and Y430C mESCs. a) RT-qPCR measuring mRNA of c-myc, Klf4, Oct4 and 
Nanog in mESCs after treatment with 300nM JQ1+, relative to that in untreated cells (JQ1-). Data are represented 
as mean +/- SEM from 3 technical replicates. b) RT-qPCR measuring mRNA for Klf4, Oct4 and Nanog in WT and 
BRD4Y430C mESCs. mRNA concentration is shown relative to WT set at 1. Data are represented as mean +/- SEM 
from 3 biological replicates. c) Heatmaps show enrichment of 4sU-seq data in WT and BRD4Y430C cells over transcri-
bed regions (-1kb, TSS and +3kb) (mm9_refseq). d) Scatter plot of the 4sU-seq data in WT and BRD4Y430C cells, 
highlighting pluripotency genes in blue (Nanog, Sox2, Klf4, Esrrb, Pou5f1). Red dashed line shows best fitted line. 
Pearson correlation coefficient=0.98. e and f) UCSC browser screenshot showing 4SU-seq reads per 10 million 
over (e) the Nanog locus and (f) the Klf4 super-enhancer in WT and BRD4Y430C cells and ChIP-seq tracks for various 
histone modifications and DNaseI hypersensitivity in WT cells. Genome co-ordinates (Mb) are from the mm9 

























































Figure 3. Increased G2/M checkpoint activation in Y430C mESCs. a) Graph shows average number of WT and 
BRD4Y430C cells per well at 1, 2, 3  and 4 days post seeding. Data are represented as mean +/- SEM from 3 technical 
replicates.  b) Overlaid graphs show WT and BRD4Y430C cell cycle profiles, as determined by flow cytometry. Graphs 
illustrate the cell count, which correlates to propidium iodide intensity. Biological replicate in Supplementary Figure 4a. c) 
Immunoblot using antibodies against Lamin B CHK1 and CHK1-P after treatment of WT and BRD4Y430C mESCs with NCS 
and for various times (hrs) of recovery (Source data are provided as a Source Data file). Data from an independent expe-
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Figure 4. Increased size and number of 53BP1 foci after DSB induction in Y430C mESCs.  a) Immunofluorescence 
for 53BP1 in the DAPI-stained nuclei of wild-type and BRD4Y430C mESCs upon treatment with NCS and after recovery 
periods up to 20 hrs. Scale bars: 2μm. The experiment was repeated 3 times independently with similar results. b&c) 
Box-plots show area (μm2) and number of 53BP1 foci per cell, respectively, in WT and BRD4Y430C cells after treatment with 
NCS in one representative experiment. Horizontal lines within boxes show medians, boxes are inter-quartile ranges and 
whiskers are range. P-values were calculated with Mann-Whitney one-sided U test. * < 0.05, ** < 0.01, *** < 0.001. 50 cells 
per condition were examined. Data from three independent experiment are in Supplementary figure 6.
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Figure 5. Increased RIF1 and MAD2L2 foci after DSB induction in Y430C mESCs. a) Representative images of 
wild-type and BRD4Y430C mESCs upon RIF1 immunofluorescence and DAPI staining after treatment with NCS. 
Scale bars: 2μm. The experiment was repeated three times with similar results. b) Box-plot shows number of RIF1 
foci per cell, respectively, in WT and BRD4Y430C cells after treatment with NCS in one representative experiment. 
Horizontal lines within boxes show medians, boxes are inter-quartile ranges and whiskers are range. P-values were 
calculated with Mann-Whitney one-sided U test. * < 0.05, ** < 0.01, *** < 0.001. 50 cells were examined per condi-
tion. c) Representative images of wild-type and BRD4Y430C mESCs upon MAD2L2 immunofluorescence and DAPI 
staining after treatment with NCS. Scale bars: 2μm. The experiment was repeated three times with similar results 
d) Box-plot shows number of MAD2L2 foci per cell, respectively, in WT and BRD4Y430C cells after treatment with NCS 
in one representative experiment. Horizontal lines within boxes show medians, boxes are inter-quartile ranges and 
whiskers are range. P-values were calculated with Mann-Whitney one-sided U test. * < 0.05, ** < 0.01, *** < 0.001. 
50 cells were examined per condition.
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Figure 6. Evidence for DNA repair defects in CdLS a) Representative images of wild-type and BRD4Y430C mESCs 
upon RAD51 immunofluorescence and DAPI staining after treatment with NCS. Scale bar = 5 μm. The experiment 
was repeated three times with similar results b) Box-plot shows number of RAD51 foci per cell, respectively, in WT 
and BRD4Y430C cells after treatment with NCS in one representative experiment. Horizontal lines within boxes show 
medians, boxes are inter-quartile ranges and whiskers are range. P-values were calculated with Mann-Whitney 
one-sided U test. * < 0.05, ** < 0.01, *** < 0.001. 50 cells were examined per condition. c) Representative images 
of wild-type, R2298 and I1206del LCLs upon 53BP1 and DAPI immunofluorescence. Scale bar = 5 μm. The experi-
ment was repeated three times with similar results. d&e) Box-plots show number of 53BP1 foci per cell and area of 
53BP1 foci (μm2), respectively, in WT, R2298H and I1206del LCLs in one representative experiment. Horizontal 
lines within boxes show medians, boxes are inter-quartile ranges and whiskers are range. P-values were calculated 
with Mann-Whitney one-sided U test. * < 0.05, ** < 0.01, *** < 0.001. 50 cells were examined per condition.
